HYDROFLUMETHIAZIDE AND RESERPINE

Clinical safety rating: safe

MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.

How it works

Hydroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine is an indole alkaloid that depletes catecholamines from central and peripheral nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and vasodilation.

What the body does with it

Metabolism	Hydroflumethiazide: minimally metabolized, primarily excreted unchanged in urine. Reserpine: extensively metabolized in the liver via hydrolysis and conjugation, with some deacetylation; active metabolites are formed.
Excretion	Hydroflumethiazide: Primarily renal excretion (60-80% as unchanged drug), with minor biliary/fecal elimination (10-20%). Reserpine: Extensive hepatic metabolism; metabolites excreted renally and fecally. Less than 1% of reserpine is excreted unchanged in urine.
Half-life	Hydroflumethiazide: Terminal half-life 12-15 hours, supporting once- or twice-daily dosing. Reserpine: Terminal half-life 50-100 hours (average 70 hours), requiring days to weeks for full washout; clinical effects persist beyond drug presence due to irreversible binding to vesicular monoamine transporters.
Protein binding	Hydroflumethiazide: ~50-70% bound to plasma proteins (primarily albumin). Reserpine: >95% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
Volume of Distribution	Hydroflumethiazide: Vd 0.4-0.6 L/kg, indicating distribution primarily in extracellular fluid. Reserpine: Vd 1-2 L/kg, reflecting extensive tissue binding (adipose, brain, adrenergic neurons).
Bioavailability	Hydroflumethiazide: Oral bioavailability ~70% (first-pass metabolism <30%). Reserpine: Oral bioavailability ~50% due to extensive hepatic first-pass metabolism.
Onset of Action	Hydroflumethiazide: Diuretic effect begins within 2 hours (oral), peak at 4-6 hours. Reserpine: Hypotensive effect onset delayed (3-7 days oral) due to gradual depletion of catecholamines; full effect may require 2-3 weeks.
Duration of Action	Hydroflumethiazide: Duration 12-24 hours (oral). Reserpine: Hypotensive effect lasts 1-2 weeks after drug discontinuation due to irreversible monoamine depletion; recovery of normal catecholamine levels may take weeks.

Classification & Brands

Dosing & administration

One tablet (hydroflumethiazide 50 mg / reserpine 0.125 mg) orally once daily.

Dosage form	TABLET
Renal impairment	Contraindicated if GFR <30 mL/min. For GFR 30-50 mL/min, use with caution and monitor electrolytes; no standard dose reduction specified.
Liver impairment	Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B); no specific dose adjustment provided.
Pediatric use	Not recommended due to lack of safety and efficacy data in pediatric patients.
Geriatric use	Initiate at lowest possible dose (e.g., half tablet daily) to minimize orthostatic hypotension and electrolyte disturbances; monitor renal function and electrolytes closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.

FDA category	Animal
Breastfeeding	Hydroflumethiazide excreted in breast milk in low amounts; reserpine excreted in breast milk (M/P ratio not well established). Potential for neonatal adverse effects: diuresis, electrolyte imbalance, respiratory depression. Avoid breastfeeding or use caution; alternative therapy recommended.
Teratogenic Risk	Pregnancy Category C. First trimester: thiazides cross placenta, possible placental insufficiency. Second/third trimester: risk of fetal/neonatal jaundice, thrombocytopenia, electrolyte disturbances. Reserpine increases risk of neonatal respiratory depression, bradycardia, hypotonia, hypothermia, and poor feeding.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Common Effects	Depression
Serious Effects

Absolute Contraindications

Anuria, hypersensitivity to thiazides or sulfonamides, severe renal impairment (CrCl <30 mL/min), hypersensitivity to reserpine, history of electroconvulsive therapy, peptic ulcer, ulcerative colitis, and concomitant use with MAOIs or electroconvulsive therapy.

Clinical Precautions

Precautions

Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, hypotension, mental depression, peptic ulcer disease, and pancreatitis.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

HYDROFLUMETHIAZIDE AND RESERPINE

Clinical safety rating: safe

MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.

How it works

What the body does with it

Metabolism	Hydroflumethiazide: minimally metabolized, primarily excreted unchanged in urine. Reserpine: extensively metabolized in the liver via hydrolysis and conjugation, with some deacetylation; active metabolites are formed.
Excretion	Hydroflumethiazide: Primarily renal excretion (60-80% as unchanged drug), with minor biliary/fecal elimination (10-20%). Reserpine: Extensive hepatic metabolism; metabolites excreted renally and fecally. Less than 1% of reserpine is excreted unchanged in urine.
Half-life	Hydroflumethiazide: Terminal half-life 12-15 hours, supporting once- or twice-daily dosing. Reserpine: Terminal half-life 50-100 hours (average 70 hours), requiring days to weeks for full washout; clinical effects persist beyond drug presence due to irreversible binding to vesicular monoamine transporters.
Protein binding	Hydroflumethiazide: ~50-70% bound to plasma proteins (primarily albumin). Reserpine: >95% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
Volume of Distribution	Hydroflumethiazide: Vd 0.4-0.6 L/kg, indicating distribution primarily in extracellular fluid. Reserpine: Vd 1-2 L/kg, reflecting extensive tissue binding (adipose, brain, adrenergic neurons).
Bioavailability	Hydroflumethiazide: Oral bioavailability ~70% (first-pass metabolism <30%). Reserpine: Oral bioavailability ~50% due to extensive hepatic first-pass metabolism.
Onset of Action	Hydroflumethiazide: Diuretic effect begins within 2 hours (oral), peak at 4-6 hours. Reserpine: Hypotensive effect onset delayed (3-7 days oral) due to gradual depletion of catecholamines; full effect may require 2-3 weeks.
Duration of Action	Hydroflumethiazide: Duration 12-24 hours (oral). Reserpine: Hypotensive effect lasts 1-2 weeks after drug discontinuation due to irreversible monoamine depletion; recovery of normal catecholamine levels may take weeks.

Classification & Brands

Dosing & administration

One tablet (hydroflumethiazide 50 mg / reserpine 0.125 mg) orally once daily.

Dosage form	TABLET
Renal impairment	Contraindicated if GFR <30 mL/min. For GFR 30-50 mL/min, use with caution and monitor electrolytes; no standard dose reduction specified.
Liver impairment	Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B); no specific dose adjustment provided.
Pediatric use	Not recommended due to lack of safety and efficacy data in pediatric patients.
Geriatric use	Initiate at lowest possible dose (e.g., half tablet daily) to minimize orthostatic hypotension and electrolyte disturbances; monitor renal function and electrolytes closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

MAOIs can cause excitability and hypertension Can cause depression and suicidal ideation.

FDA category	Animal
Breastfeeding	Hydroflumethiazide excreted in breast milk in low amounts; reserpine excreted in breast milk (M/P ratio not well established). Potential for neonatal adverse effects: diuresis, electrolyte imbalance, respiratory depression. Avoid breastfeeding or use caution; alternative therapy recommended.
Teratogenic Risk	Pregnancy Category C. First trimester: thiazides cross placenta, possible placental insufficiency. Second/third trimester: risk of fetal/neonatal jaundice, thrombocytopenia, electrolyte disturbances. Reserpine increases risk of neonatal respiratory depression, bradycardia, hypotonia, hypothermia, and poor feeding.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Common Effects	Depression
Serious Effects

Absolute Contraindications

Clinical Precautions

Precautions

Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, hypotension, mental depression, peptic ulcer disease, and pancreatitis.

Clinical Tips & Counseling

Drug interactions

Loading safety data…